Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Profit Outlook
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Profit Outlook
We feel now is a pretty good time to analyse Heron Therapeutics, Inc.'s (NASDAQ:HRTX) business as it appears the company may be on the cusp of a considerable accomplishment. Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The US$377m market-cap company posted a loss in its most recent financial year of US$182m and a latest trailing-twelve-month loss of US$120m shrinking the gap between loss and breakeven. As path to profitability is the topic on Heron Therapeutics' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.
我們認爲現在是分析 Heron Therapeutics, Inc. 的好時機。”s(納斯達克股票代碼:HRTX)的業務看來該公司可能正處於取得重大成就的風口浪尖。生物技術公司Heron Therapeutics, Inc. 致力於開發治療方法,以滿足未滿足的患者需求。這家市值3.77億美元的公司公佈其最近一個財政年度的虧損爲1.82億美元,最近十二個月的虧損爲1.2億美元,縮小了虧損與盈虧平衡之間的差距。由於盈利之路是Heron Therapeutics投資者心目中的話題,我們決定評估市場情緒。在本文中,我們將介紹對公司增長的預期以及分析師預計何時實現盈利。
Heron Therapeutics is bordering on breakeven, according to the 3 American Biotechs analysts. They expect the company to post a final loss in 2025, before turning a profit of US$14m in 2026. The company is therefore projected to breakeven around 2 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 59% year-on-year, on average, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.
三位美國生物技術分析師表示,Heron Therapeutics已接近盈虧平衡。他們預計,該公司將在2025年公佈最終虧損,然後在2026年實現1400萬美元的盈利。因此,預計從今天起大約2年後,該公司將實現盈虧平衡。爲了在2026年之前達到盈虧平衡點,公司每年必須以多快的速度增長?從分析師的估計來看,事實證明,他們預計公司平均同比增長59%,這相當樂觀!如果業務增長速度放緩,則盈利的時間將比預期的晚。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240215/0-e5f14792b96db98d8bdd334c595dc8a2-0-c877f06993ff57ef77d004b8733fbb89.png/big)
Given this is a high-level overview, we won't go into details of Heron Therapeutics' upcoming projects, though, keep in mind that generally a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
鑑於這是一個高層次的概述,我們不會詳細介紹Heron Therapeutics即將推出的項目,但請記住,生物技術公司的現金流通常不穩定,這取決於公司所處的產品類型和開發階段。因此,高增長率並非不尋常,尤其是在公司處於投資期時。
Before we wrap up, there's one issue worth mentioning. Heron Therapeutics currently has negative equity on its balance sheet. Accounting methods used to deal with losses accumulated over time can cause this to occur. This is because liabilities are carried forward into the future until it cancels. These losses tend to occur only on paper, however, in other cases it can be forewarning.
在我們總結之前,有一個問題值得一提。Heron Therapeutics目前的資產負債表上有負資產。用於處理一段時間內累積的損失的會計方法可能會導致這種情況的發生。這是因爲負債會結轉到未來,直到註銷。這些損失往往只發生在紙面上,但是,在其他情況下,這可能是預先警告。
Next Steps:
後續步驟:
There are key fundamentals of Heron Therapeutics which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Heron Therapeutics, take a look at Heron Therapeutics' company page on Simply Wall St. We've also compiled a list of important factors you should look at:
本文未涵蓋Heron Therapeutics的關鍵基礎知識,但我們必須再次強調,這只是一個基本的概述。要更全面地了解Heron Therapeutics,請查看 Heron Therapeutics 在 Simply Wall St 上的公司頁面。我們還整理了一份你應該考慮的重要因素清單:
- Valuation: What is Heron Therapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Heron Therapeutics is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Heron Therapeutics's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:Heron Therapeutics 今天的價值是多少?價格中是否已經考慮了未來的增長潛力?我們的免費研究報告中的內在價值信息圖有助於可視化Heron Therapeutics目前是否被市場定價錯誤。
- 管理團隊:一支經驗豐富的管理團隊掌舵增強了我們對業務的信心——看看誰是Heron Therapeutics董事會成員以及首席執行官的背景。
- 其他表現優異的股票:還有其他股票可以提供更好的前景並有良好的往績記錄嗎?在這裏瀏覽我們免費列出的這些優質股票。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。